C. Difficile

The first FDA-approved fecal microbiota product maintained a positive safety profile in the largest safety evaluation to date with up to 2 years of safety data.

Coverage this week included how COVID-19 vaccines in patients with cancer fared; analysis of non-COVID-19 adult vaccines; a company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b; and how a hospital modified testing for C difficile.

This study explores the effectiveness of PCR and toxin EIA testing in predicting C difficile infection (CDI) outcomes. The research reveals that patients with negative toxin results were less likely to experience CDI recurrence within 30 days.

Rebyota, the first FDA-approved microbiota-based live biotherapeutic for preventing recurrent Clostridioides difficile infection (rCDI), has been the subject of a groundbreaking safety analysis.

Hospital posits that testing for C diff in patients without symptoms inflates rate of hospital-acquired infection with cases of asymptomatic colonization.

A new study looks at vitamin D’s role in acting as a deterrent to the proliferation of C diff bacteria.

Which COVID-19 vaccine is associated with Guillain-Barré Syndrome? What's the newest C difficile therapy? Contagion's weekly infectious disease recap has you covered.

Lumen Bioscience's C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.

Here is a brief report of 5 cases of the use of fecal microbiota, live-jslm (Rebyota) in the management of recurrent Clostridioides difficile infection.

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been busy this year in Washington DC with an FDA event and their Summit and Advocacy Day with lawmakers.

Inhibiting production of para-cresol could be effective against Clostridioides difficile infection by reducing the pathogen’s ability to compete with other bacteria in the gut microbiome, a new study found.

In a comprehensive economic evaluation, researchers assessed the cost-effectiveness of monoclonal antibodies as a preventive strategy for COVID-19.

Stay informed about the long-term effects of COVID-19, prevention strategies for recurrent C diff, and the emerging threat of drug-resistant Candida auris.

FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.

From FDA recalls to a new COVID-19 variant, infectious disease news did not slow down in June. Catch up with Contagion's monthly recap of our most-clicked articles.

Competition among species has therapeutic implications, the authors found.

In phase 3 studies, the company’s investigational therapy, aztreonam-avibactam (ATM-AVI), had favorable results over other treatments used for complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).

As the first line of acute care, emergency departments are key stewards of antibiotics.

A study of hospitalized patients with diarrhea found that collecting stool samples and testing all of them identified almost 30% more cases of C. diff than the standard of care.

Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.

Due to worsening headaches and unrevealing cross-sectional imaging and ascites fluid analyses, this patient's differential evolved toward a central nervous system source.

Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.

Joseph Reilly, BS, PharmD, BCGP, reviews the positive economic impact of use of live-jslm for treatment of CDI in a hospital setting.

Experts comment on the measures that need to be taken to prevent or control the spread of CDI in the healthcare setting.

The update includes several different infections, and offers brief descriptions of significant clinical trials, resistance mechanisms, and antimicrobial susceptibility testing methods for each of the pathogens.